(AAN abst.) Safety and tolerability of a modified ublituximab dosing regimen: ENHANCE study updates on: May 05, 2026, 09:00:17 pm #1 Presented at the recent (April) annual AAN conference--"Safety and tolerability of a modified ublituximab dosing regimen: Updates from the ENHANCE study": 2026 American Academy of Neurology Abstract Website index.mirasmart.com Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
